LENZ Therapeutics, Inc.
LENZ · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.76 | 0.00 | -0.80 | -0.74 |
| FCF Yield | -0.68% | -1.43% | -2.28% | -1.16% |
| EV / EBITDA | -78.70 | -46.71 | -40.59 | -50.98 |
| Quality | ||||
| ROIC | -9.72% | -8.13% | -8.76% | -7.41% |
| Gross Margin | 99.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.51 | 0.77 | 1.10 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,596,147.05% | 1,709,875.95% | -100.00% | -100.00% |
| Free Cash Flow Growth | 23.16% | 27.30% | -75.13% | 14.30% |
| Safety | ||||
| Net Debt / EBITDA | 1.50 | 2.17 | 1.29 | 1.24 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.13 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,429.28 | 0.00 | 0.00 | 0.00 |